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Abstract
Objective
To assess whether the use of complementary and alternative medicines therapies (CAMs)
for prostate cancer and/or its treatment side effects by long-term survivors is associated
with selected socio-demographic, clinical, health-related quality-of-life (HRQOL) and/or psy-
chological factors.
Design, setting and participants
The Prostate Cancer Care and Outcomes Study (PCOS) is a population-based cohort study
of men with prostate cancer who were aged less than 70 years at diagnosis in New South
Wales, Australia. Included in these analyses were men who returned a 10-year follow-up
questionnaire, which included questions about CAM use.
Methods
Validated instruments assessed patient’s HRQOL and psychological well-being. Poisson
regression with robust variance estimation was used to estimate the adjusted relative risks
of current CAM use for prostate cancer according to socio-demographic, clinical, HRQOL
and psychological factors.
Results
996 of 1634 (61%) living PCOS participants completed the 10-year questionnaire. Of these
996 men, 168 (17%) were using CAMs for prostate cancer and 525 (53%) were using CAMs
for any reason (including prostate cancer). Those using CAM for prostate cancer were more
likely to be regular or occasional support group participants (vs. no participation RR = 2.02;
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95%CI 1.41–2.88), born in another country (vs. Australian born RR = 1.59; 95%CI 1.17–
2.16), have received androgen deprivation treatment (ADT) since diagnosis (RR = 1.60;
95%CI 1.12–2.28) or in the past two years (RR = 2.34; 95%CI 1.56–3.52). CAM use was
associated with greater fear of recurrence (RR = 1.29; 95%CI 1.12–1.48), cancer-specific
distress (RR = 1.15; 95%CI 1.01–1.30), cancer-specific hyperarousal (RR = 1.17; 95%CI
1.04–1.31), cancer locus of control (RR = 1.16; 95%CI 1.01–1.34) and less satisfaction with
medical treatments (RR = 0.86; 95%CI 0.76–0.97), but not with intrusive thinking, cognitive
avoidance, depression, anxiety or any HRQOL domains.
Conclusions
In this study, about one in six long term prostate cancer survivors used CAMs for their pros-
tate cancer with use centred around ADT, country of birth, distress, cancer control, fear of
recurrence and active help seeking.
Introduction
The use of complementary and alternative medicines (CAMs) by cancer patients remains an
emotionally charged issue. Critics of these therapies often cite the paucity of scientific evidence
justifying their use, their potential for adverse effects, their potential for interaction with con-
ventional treatments, the possibility that patients might use them as alternatives to conven-
tional treatments and the potential for financial exploitation of vulnerable people [1–3].
Advocates, on the other hand, often point to the limited evidence supporting the use of some
conventional medicines [4], while others argue that CAMs should not be held to the same
standards of proof as evidence-based medicines [5]. Regardless of the arguments for and
against, CAM use by cancer patients is a worldwide phenomenon [1] that is likely to grow as
cancer incidence and survival increase. Consequently, it is important for clinicians to be aware
of the types of CAMs that cancer patients are likely to use and the factors that motivate their
use, particularly for patients with cancer types known to be associated with this use.
The National Cancer Institute’s Office of Cancer Complementary and Alternative Medi-
cines (OCCAM) defines ‘complementary and alternative medicine’ as “any medical system,
practice, or product that is not thought of as standard care” [6]. According to the OCCAM,
broad categories of CAMs include alternative medical systems, energy therapies, exercise ther-
apies, manipulative and body-based methods, mind-body interventions, nutritional therapeu-
tics, pharmacologic and biologic treatments and spiritual therapies. Previous research has
shown that CAM use is common amongst prostate cancer patients. A 2011 systematic review
reported that in 39 studies, the median prevalence of CAM use following a diagnosis of pros-
tate cancer was 30% [7]. Previous studies have also identified various predictors of CAM use
amongst prostate cancer patients such as higher education [8,9] and more advanced or aggres-
sive cancer at diagnosis [10,11]. To our knowledge, however, there have been no studies that
have examined factors associated with CAM use for prostate cancer exclusively among long-
term survivors. This is despite the fact that substantial numbers of men are living with a diag-
nosis of prostate cancer and the adverse consequences that can follow for many years after
diagnosis [12]. In Australia, for example, prostate cancer is expected to remain the most com-
monly diagnosed non-cutaneous cancer among males in 2017, accounting for 12% of all
reportable cancers [13]. With five-year relative survival of around 95% [13], and nearly 100%
The use of complementary and alternative medicines for prostate cancer by long-term survivors
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for those diagnosed with localised disease [14], there will be a significant and increasing num-
ber of Australian men living with a previous diagnosis of prostate cancer.
In this cross-sectional analysis, we used information from a group of long-term survivors of
prostate cancer (mean = 10 years) from Australia’s most populous state, New South Wales
(NSW), to examine whether ‘current CAM use for prostate cancer and/or its treatment side
effects’ (hereafter abbreviated as ‘CAM use for prostate cancer’) is associated with selected
socio-demographic, clinical, health-related quality-of-life (HRQOL) and/or psychological
factors.
Materials and methods
Study sample
The Prostate Cancer Care and Outcomes Study (PCOS) is a population-wide longitudinal
cohort study conducted in NSW, Australia, with a primary objective of assessing the effects of
various treatments on HRQOL after diagnosis of prostate cancer. A total of 3195 men aged less
than 70 years with histopathologically confirmed T1-4 prostate cancer diagnosed between
October 2000 and October 2002 were identified through the NSW Cancer Registry and after
consent had been given by their doctor, were invited to participate in PCOS. Of these 1995
completed a baseline interview (S1 Fig). As of January 2011, 1634 men were still alive of whom
1427 remained in PCOS and were invited to participate in a 10-year follow-up survey (mean
of 10 years after diagnosis; range 9–12 years) assessing their use of CAMs and various HRQOL
and psychological domains. Of the 1634 men, 996 (61%) completed and returned the 10-year
questionnaire. Additional details of the initial recruitment process for PCOS are provided else-
where [15,16]. PCOS was approved by the human research ethics committees of the Cancer
Council NSW, the Cancer Institute NSW, and the NSW Department of Health. The 10-year
follow-up survey was approved by the Cancer Council NSW Human Research Ethics Commit-
tee (Approval number: 2010#244).
Data collection
Clinical and socio-demographic data. Baseline clinical data were collected for each par-
ticipant by either a trained field worker or the treating doctor using a data collection form and
protocol. These data were collected between 12 and 24 months after the histological diagnosis
of prostate cancer and included prostate-specific antigen (PSA) level at diagnosis, Gleason
score and clinical stage at diagnosis, and treatment received within 12 months of diagnosis.
Place and socio-economic status of the man’s place of residence at diagnosis were based on the
Accessibility/Remoteness Index of Australia (ARIA+) [17] and the Socio-Economic Indexes
for Areas (SEIFA) [18] respectively. Highest level of education completed was self-reported in
the baseline PCOS survey. Information on prostate cancer treatments received was obtained
from the treating doctor’s records (diagnosis to 12 months) and from linked administrative
health datasets (diagnosis to current follow-up). For each man who consented, treatment data
were obtained from Medicare Australia and NSW Health’s Admitted Patient Data Collection
[19]. Clinical and socio-demographic information obtained in the 10-year survey included
current place of residence, employment status, marital status, support group participation and
the man’s knowledge of whether the cancer has spread.
Psychological and health-related quality-of-life domains. A number of previously vali-
dated psychological and HRQOL instruments were included in the 10-year survey including: a
6-item course of cancer subscale from the Cancer Locus of Control scale measuring each
man’s perceived control of the course of their cancer [20]; Kornblith’s 5-item Cancer Fear of
Recurrence scale [21]; the 22-item Impact of Event Scale-Revised (IES-R) [22] measuring
The use of complementary and alternative medicines for prostate cancer by long-term survivors
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distress, hyperarousal, intrusive thinking and cognitive avoidance associated with having pros-
tate cancer; the14-item Hospital Anxiety and Depression Scale (HADS) [23] measuring anxi-
ety and depression; the 26-item Expanded Prostate cancer Index Composite Short Form
(EPIC-26) [24] measuring urinary incontinence, urinary irritative/obstructive, bowel, sexual
and hormonal summary scores, and also measuring urinary, bowel and sexual bother scores
from a subset of questions common to both the University of California-Los Angeles Prostate
Cancer Index (UCLA-PCI) [25] and the EPIC-26; and the 12-item Short Form-12 (SF-12) [26]
scale measuring the mental and physical dimensions of HRQOL. Satisfaction with medical
treatments was measured on a 1-item 5-point Likert scale from the Expanded Prostate cancer
Index Composite Long Form (EPIC-50) [27]. For each psychological domain, higher scores
indicate higher levels of the psychological attribute. For each HRQOL domain, higher scores
indicate better HRQOL (which corresponds to less bother for the bother domains).
Complementary and alternative medicines. Questions relating to CAM use were broadly
based on the I-CAM-Q [28], but with modifications to address issues specific to prostate can-
cer survivors. While the I-CAM-Q has been a widely used instrument for measuring CAM
use, it is yet to be fully evaluated. CAMs comprised dietary supplements, non-specialist treat-
ments and self-help therapies. Dietary supplements included vitamins, minerals and herbal
medicines. Non-specialist treatments were defined as treatments provided by practitioners
other than a medical specialist such as acupuncture, biofeedback and homeopathy. Self-help
therapies were defined as therapies that the survivor could do themselves such as relaxation
techniques, meditation, yoga or prayer. For each category of CAM, men were asked about
their current and previous use of those therapies for prostate cancer, and their current use of
those therapies for other health conditions or general well-being.
Statistical methods
Poisson regression with robust variance estimation [29] was used to estimate the adjusted rela-
tive risks of current CAM use for prostate cancer according to socio-demographic characteris-
tics, clinical characteristics, psychological and HRQOL domains. The dependent variable in all
regression models was CAM use for prostate cancer (yes or no). Independent variables
included age (<65, 65–69, 70–74, 75+ years; age ranged from 52 to 80 years), education (uni-
versity or college degree, high school, less than high school), socio-economic status of place of
residence (divided into quintiles using SEIFA), place of residence (major city, inner regional,
outer regional/ remote/ very remote based on ARIA+), health insurance (private health insur-
ance- with extras, private health insurance- without extras, Medicare only), employment status
(in full time paid work, in part time paid work, retired/unemployed, self-employed), married
or in defacto partner relationship (no, yes), participation in a support group (no contact with
support groups, receive newsletter only, participate regularly or occasionally), country of birth
(Australia, elsewhere), overall cancer severity at diagnosis (localised low risk, localised inter-
mediate risk, localised high risk, stage T3-4) [30] and treatments used since diagnosis (active
surveillance/watchful waiting (AS/WW), prostatectomy, external beam radiotherapy (EBRT)/
brachytherapy, bone EBRT, androgen deprivation treatment (ADT), chemotherapy/bisphos-
phonates). Other independent variables included PSA level at diagnosis (<4, 4 to<10, 10 to
<20, 20+ng/mL), Gleason score at diagnosis (<7, 7, >7), clinical stage at diagnosis (T1a-c,
T2a-c, T3a-c/T4a), knowledge of cancer spread (no, yes) and prostate cancer treatments used
in the past two years. In order to avoid collinearity, however, these other variables were not
included in models simultaneously with overall cancer severity at diagnosis and treatments
used since diagnosis. Tests for linear associations between CAM use and socio-demographic
and clinical characteristics were performed by substituting the nominal versions of socio-
The use of complementary and alternative medicines for prostate cancer by long-term survivors
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demographic and/or clinical variables with continuous or ordinal versions where appropriate.
For ordinal variables that were not interval scaled (eg. health insurance), consecutive integers
were used for coding when testing for linear associations. Psychological and HRQOL variables
were included one at a time as linear continuous independent variables in regression models
after standardising each variable to have variance equal to one. Hence, relative risks for psy-
chological and HRQOL variables indicate the change in the probability/risk of CAM use per
standard deviation increase in the variable [31]. Subjects with missing data for any psychologi-
cal or HRQOL domain were excluded from analyses relating to that particular domain.
Results
Of the 996 men who returned a 10-year follow-up questionnaire, 168 (16.9%) were current
users of CAMs for prostate cancer and 525 (52.7%) were current users of CAMs for any reason
(including prostate cancer) (Table 1). The most common categories of CAMs used for prostate
cancer were dietary supplements (n = 115, 11.6%), and self-help activities (n = 73, 7.3%). The
reasons for and sources of information on CAM use for prostate cancer are shown in S1 Table.
Men were more likely to be CAM users for prostate cancer if they were regular or occa-
sional participants in a support group (vs. no contact with support groups, RR = 2.02; 95%CI
1.41–2.88), born in another country (vs. Australian born RR = 1.59; 95%CI 1.17–2.16) or ever
received androgen deprivation treatment (ADT) (RR = 1.60; 95%CI 1.12–2.28) (Table 2).
CAM use for prostate cancer was also significantly higher among men who received ADT in
the past two years (RR = 2.34; 95%CI 1.56–3.52) (Table 3).
While cancer severity at diagnosis was not associated with CAM use in the fully-adjusted
model (p = 0.366; p-trend = 0.071) in Table 2, when ‘treatments used since diagnosis’ was
removed from the model then higher risk prostate cancer at diagnosis became significantly
Table 1. Categories and subcategories of CAMs currently used for prostate cancer and/or treatment side effects
and for any reason.
CAMs currently used ^ For prostate cancer and/or treatment side effects
n (% of 996)
For any reason
n (% of 996)
Any CAM: 168 (16.9) 525 (52.7)
Dietary supplements: 115 (11.6) 464 (46.6)
Glucosamine < 1% 164 (16.5)
Herbal † 41 (4.1) 87 (8.7)
Minerals 45 (4.5) 129 (13.0)
Multivitamins 31 (3.1) 104 (10.4)
Omega-3 37 (3.7) 254 (25.5)
Vitamins 44 (4.4) 157 (15.8)
Other 18 (1.8) 85 (8.5)
Non-medical treatments: # 17 (1.7) 84 (8.4)
Self help activities: 73 (7.3) 125 (12.6)
Meditation 14 (1.4) <5%
Prayer 56 (5.6) 77 (7.7)
Frequencies shown for CAM subcategories used by over 5% of men for any reason or by over 1% of men for prostate
cancer and/or treatment side effects
^ Men may use more than one category or subcategory of CAM
† Includes herbs and plant extracts
# No single non-medical treatment subcategory was used by over 5% of men for any reason or by over 1% of men for
prostate cancer.
https://doi.org/10.1371/journal.pone.0193686.t001
The use of complementary and alternative medicines for prostate cancer by long-term survivors
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Table 2. Associations between current CAM use for prostate cancer and/or its treatment side effects and socio-demographic/clinical characteristics for Australian
long-term prostate cancer survivors.
Characteristic Current CAM use for prostate cancer and/or treatment side effects (n = 996)
Non-user
n (%)
User
n (%)
Age-adjusted
RR1 
Fully-adjusted
RR2 
p-nominal
p-trend^
828 (83.1) 168 (16.9)
Age (years)
<65 132 (80.5) 32 (19.5) ref. ref. 0.240
65–69 223 (83.5) 44 (16.5) 0.84 (0.56, 1.28) 0.78 (0.50, 1.22) 0.080
70–74 245 (81.9) 54 (18.1) 0.93 (0.62, 1.37) 0.82 (0.52, 1.30)
75–80 228 (85.7) 38 (14.3) 0.73 (0.48, 1.12) 0.63 (0.39, 1.01)
Education
University or college degree 237 (79.8) 60 (20.2) ref. ref. 0.260
High school 570 (85.1) 100 (14.9) 0.74 (0.55, 0.99) 0.90 (0.67, 1.21) 0.999
Less than high school 18 (72.0) 7 (28.0) 1.50 (0.76, 2.96) 1.56 (0.78, 3.09)
Missing + 3 (75.0) 1 (25.0)
Socio-economic status of residence area
1- Highest SES 287 (82.9) 59 (17.1) ref. ref. 0.903
2 172 (84.3) 32 (15.7) 0.93 (0.63, 1.37) 0.86 (0.56, 1.31) 0.379
3 176 (82.2) 38 (17.8) 1.03 (0.71, 1.49) 0.87 (0.56, 1.34)
4 121 (84.0) 23 (16.0) 0.94 (0.60, 1.46) 0.83 (0.49, 1.43)
5- Lowest SES 70 (84.3) 13 (15.7) 0.92 (0.53, 1.60) 0.72 (0.35, 1.48)
Missing + 2 (40.0) 3 (60.0)
Place of residence
Major city 480 (82.8) 100 (17.2) ref. ref. 0.419
Inner regional 226 (85.0) 40 (15.0) 0.87 (0.62, 1.22) 0.99 (0.68, 1.45) 0.195
Outer regional/ remote/ very remote 121 (81.8) 27 (18.2) 1.06 (0.72, 1.56) 1.33 (0.83, 2.14)
Missing + 1 (50.0) 1 (50.0)
Health insurance
Private health insurance- with extras 477 (81.7) 107 (18.3) ref. ref. 0.195
Private health insurance- without extras 125 (81.7) 28 (18.3) 1.01 (0.69, 1.48) 1.00 (0.67, 1.50) 0.094
Medicare 224 (87.5) 32 (12.5) 0.69 (0.48, 0.99) 0.71 (0.49, 1.04)
Missing + 2 (66.7) 1 (33.3)
Employment status
In full time paid work 110 (84.6) 20 (15.4) ref. ref. 0.386
In part time paid work 89 (83.2) 18 (16.8) 1.17 (0.64, 2.12) 1.32 (0.72, 2.44) n/a
Retired/Unemployed 617 (83.4) 123 (16.6) 1.23 (0.76, 1.98) 1.23 (0.73, 2.07)
Self-employed 10 (58.8) 7 (41.2) 2.84 (1.40, 5.76) 2.02 (0.90, 4.53)
Missing + 2 (100.0) 0 (0.0)
Married or in defacto partner relationship
No 142 (85.5) 24 (14.5) ref. ref. 0.340
Yes 685 (82.6) 144 (17.4) 1.20 (0.80, 1.78) 1.23 (0.80, 1.89) n/a
Missing + 1 (100.0) 0 (0.0)
Participate in a support group
No contact with support groups 655 (85.1) 115 (14.9) ref. ref. <0.001
Receive newsletter only 124 (81.0) 29 (19.0) 1.27 (0.88, 1.84) 1.26 (0.85, 1.85) n/a
Participate regularly or occasionally 49 (67.1) 24 (32.9) 2.20 (1.52, 3.17) 2.02 (1.41, 2.88)
Country of birth
In Australia 656 (85.4) 112 (14.6) ref. ref. 0.003
In another country 172 (75.8) 55 (24.2) 1.66 (1.24, 2.21) 1.59 (1.17, 2.16) n/a
(Continued)
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associated with an increased likelihood of CAM use (p = 0.010; p-trend = 0.001). Similarly,
while knowledge of cancer spread was not associated with CAM use in the fully-adjusted
model (p = 0.177) in Table 3, when ‘treatments used in past 2 years’ was removed from the
model then knowledge of cancer spread became significantly associated with an increased like-
lihood of CAM use (p<0.001).
Additional adjustment for selected individual psychological domains—fear of recurrence,
cancer-specific distress, hyperarousal, cognitive avoidance and anxiety—did not substantively
alter the estimated adjusted RRs and 95% CIs for the associations between CAM use for pros-
tate cancer and patient characteristics (data available on request).
For the psychological domains, CAM use for prostate cancer was associated with greater per-
ceived control of cancer course (RR = 1.16; 95%CI 1.01–1.34), fear of recurrence (RR = 1.29;
95%CI 1.12–1.48), cancer-specific distress (RR = 1.15; 95%CI 1.01–1.30) and hyperarousal
(RR = 1.17; 95%CI 1.04–1.31). CAM use for prostate cancer was more likely with less satisfac-
tion with medical treatments (RR = 0.86; 95%CI 0.76–0.97), but was not associated with intru-
sive thinking, cognitive avoidance, depression, anxiety or any of the HRQOL domains (p-values
ranged from 0.055 to 0.890) (Fig 1).
Discussion
In this cohort of long-term prostate cancer survivors, just over half of men used CAMs for any
reason and about one in six used them for prostate cancer. Men were more likely to use CAMs
Table 2. (Continued)
Characteristic Current CAM use for prostate cancer and/or treatment side effects (n = 996)
Non-user
n (%)
User
n (%)
Age-adjusted
RR1 
Fully-adjusted
RR2 
p-nominal
p-trend^
Missing + 0 (0.0) 1 (100.0)
Overall cancer severity at diagnosis†
Localised low risk 296 (86.8) 45 (13.2) ref. ref. 0.366
Localised intermediate risk 298 (83.0) 61 (17.0) 1.30 (0.91, 1.85) 1.21 (0.82, 1.79) 0.071
Localised high risk 136 (77.3) 40 (22.7) 1.76 (1.19, 2.58) 1.32 (0.85, 2.04)
Stage T3-4 50 (73.5) 18 (26.5) 2.06 (1.27, 3.34) 1.62 (0.95, 2.75)
Unknown 48 (92.3) 4 (7.7) 0.59 (0.22, 1.57) 0.69 (0.25, 1.88)
Treatments used since diagnosis ^^
Active surveillance 83 (83.8) 16 (16.2) 1.14 (0.69, 1.89) 1.32 (0.76, 2.29) 0.001 #
Prostatectomy 563 (85.6) 95 (14.4) 0.89 (0.61, 1.29) 0.76 (0.51, 1.14) n/a
EBRT/Brachytherapy 310 (78.1) 87 (21.9) 1.12 (0.75, 1.66) 1.03 (0.68, 1.57)
Bone EBRT 5 (83.3) 1 (16.7) 1.27 (0.26, 6.27) 0.81 (0.14, 4.51)
Androgen deprivation treatment 237 (74.3) 82 (25.7) 1.92 (1.37, 2.67) 1.60 (1.12, 2.28)
Chemotherapy/bisphosphonates + 7 (100.0) 0 (0.0)
 Adjusted for age;
 Adjusted for age, education, socio-economic status of residence area, place of residence, health insurance, employment status, marital status, participation in a
support group, country of birth, cancer severity at diagnosis, and treatments used since diagnosis;
+ Excluded from regression analyses;
† Localised (stage 1 or 2) risk groups- low risk (PSA10, Gleason score6, and clinical stage = T1-2a), intermediate risk (10<PSA20, Gleason score = 7 or clinical
stage = T2b) high-risk (PSA >20, Gleason score>7, or clinical stage T2c); p-values values correspond to fully adjusted models;
^p-trend analysis excludes ‘missing’ and ‘unknown’ categories;
^^ Multiple treatments possible for each man and reference group for each treatment is not having had that treatment;
# p-value is for test that all RR2s equal one; Data from 10-year survey unless “at diagnosis” stated.
https://doi.org/10.1371/journal.pone.0193686.t002
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for prostate cancer if they were born in a country other than Australia, received ADT and/or
were less satisfied with the medical treatments they received. A higher likelihood of CAM use
for prostate cancer was associated with having greater cancer-related distress and/or having a
greater fear of cancer recurrence, suggesting that psychological factors may play a part in driv-
ing this behaviour. CAM use was also more likely among men with a greater belief that their
cancer course can be controlled as well as men who participated in support groups.
While there have been a number of studies that have quantitatively examined factors associ-
ated with CAM use among men diagnosed with prostate cancer, only seven of these studies
specifically measured CAM use for prostate cancer [8–11,32–34]. We consider this distinction
important, as the factors that motivate CAM use for prostate cancer are likely to differ from
Table 3. Associations between current CAM use for prostate cancer and/or its treatment side effects and other clinical characteristics for Australian long-term pros-
tate cancer survivors.
Characteristic Current CAM use for prostate cancer and/or treatment side effects (n = 996)
Non-user
n (%)
User
n (%)
Age-adjusted
RR1 
Fully-adjusted
RR2 
p-nominal
p-trend ^
828 (83.1) 168 (16.9)
PSA at diagnosis (ng/mL) †
<4 72 (84.7) 13 (15.3) ref. ref. 0.688
4 to <10 477 (84.1) 90 (15.9) 1.06 (0.62, 1.82) 1.04 (0.60, 1.79) 0.529
10 to <20 168 (84.0) 32 (16.0) 1.08 (0.59, 1.97) 0.99 (0.53, 1.85)
20+ 70 (72.2) 27 (27.8) 1.85 (1.01, 3.36) 1.29 (0.66, 2.49)
Unknown 41 (87.2) 6 (12.8) 0.85 (0.34, 2.12) 1.67 (0.60, 4.66)
Gleason score at diagnosis †
<7 452 (85.3) 78 (14.7) ref. ref. 0.963
7 284 (80.5) 69 (19.5) 1.32 (0.98, 1.77) 1.01 (0.74, 1.39) 0.499
>7 63 (77.8) 18 (22.2) 1.53 (0.97, 2.42) 0.90 (0.53, 1.52)
Unknown 29 (90.6) 3 (9.4) 0.62 (0.20, 1.89) 0.92 (0.36, 2.36)
Clinical stage at diagnosis †
T1a-c 426 (85.0) 75 (15.0) ref. ref. 0.372
T2a-c 321 (81.7) 72 (18.3) 1.24 (0.93, 1.67) 1.00 (0.73, 1.36) 0.303
T3a-c, T4a 50 (73.5) 18 (26.5) 1.81 (1.15, 2.83) 1.33 (0.80, 2.20)
Unknown 31 (91.2) 3 (8.8) 0.59 (0.19, 1.78) 0.48 (0.16, 1.49)
Knowledge of cancer spread †
No 783 (84.6) 142 (15.4) ref. ref. 0.177
Yes 45 (63.4) 26 (36.6) 2.40 (1.71, 3.38) 1.34 (0.88, 2.05) n/a
Active treatments used in past 2 years †
None 750 (85.6) 126 (14.4) ref. ref. <0.001
Androgen deprivation treatment 59 (60.8) 38 (39.2) 2.85 (2.12, 3.83) 2.34 (1.56, 3.52) n/a
Other active treatments ^^ 19 (82.6) 4 (17.4) 1.17 (0.48, 2.86) 1.01 (0.37, 2.73)
 Adjusted for age;
 Adjusted for age, education, socio-economic status of residence area, place of residence, health insurance, employment status, marital status, participation in a
support group, country of birth, PSA at diagnosis, Gleason score at diagnosis, clinical stage at diagnosis, knowledge of cancer spread and active treatments used in the
past 2 years;
† To avoid collinearity, PSA at diagnosis, Gleason score at diagnosis, clinical stage at diagnosis, knowledge of cancer spread and active treatments used in the past 2 years
were not included in models simultaneously with overall cancer severity at diagnosis and treatments used since diagnosis; p-values values correspond to fully adjusted
models.
^p-trend analysis excludes ‘missing’ and ‘unknown’ categories;
^^ Does not include men who received ADT in past 2 years; Data from 10-year survey unless “at diagnosis” stated.
https://doi.org/10.1371/journal.pone.0193686.t003
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those that motivate CAM use for other purposes. Although none of the seven previous studies
were restricted exclusively to long-term survivors, comparisons with the current study results
are informative. Consistent with the findings of the current study, CAM use was not found to
be associated with marital status in four previous studies to examine this association [8–10,32].
CAM use was found to be associated with younger age in three of six previous studies [8–
11,32–33]. In the current study, although the lowest and highest proportions of CAM users
were in the oldest and youngest age groups respectively (14% vs 20%), the association between
age and CAM use was not statistically significant (p-trend = 0.080). While higher education
has been found to be associated with CAM use in two of three previous studies [8–10], we
found little evidence for such a relationship in an Australian setting. We also found that men
who participated in prostate cancer support groups were more likely to be CAM users and this
was in agreement with the two previous studies that examined this [8,10]. Because of the cross-
sectional nature of these studies and ours, however, it is not clear whether the likelihood of
CAM use becomes raised as a consequence of joining a support group or whether support
group participants were predisposed to CAM use before joining.
The current study found that receiving ADT either at any time since diagnosis or in the
past two years was associated with an increased likelihood of CAM use, and similar findings
Fig 1. Relative risk (RR) of current CAM use for prostate cancer and/or its treatment side effects per standard deviation increase in psychological or
HRQOL domain for Australian long-term prostate cancer survivors. Adjusted for age, education, socio-economic status of residence area, place of residence,
health insurance, employment status, marital status, participation in a support group, country of birth, cancer severity at diagnosis and treatments used since
diagnosis.
https://doi.org/10.1371/journal.pone.0193686.g001
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have been reported in one other study [10]. This is consistent with the view that recipients of
ADT may use CAMs in an attempt to ameliorate the more severe side effects and risks associ-
ated with ADT in comparison to other treatments. Moreover, indicators of cancer severity
and knowledge of cancer spread were not found to be associated with CAM use in the
current study, except in the analyses not adjusted for treatments received. These results, taken
together, suggest that the increased CAM use among patients with higher risk disease charac-
teristics appears driven more by the hope of ameliorating ADT side effects than by the hope of
reducing disease risks. This interpretation is supported by two previous studies [9,32] that also
did not find an association between CAM use and disease severity, but is at odds with another
study that found increased CAM use among patients with higher Gleason score at diagnosis
[11].
We found that CAM use for prostate cancer was associated with higher levels of cancer-spe-
cific distress, cancer-specific hyperarousal and fear of cancer recurrence. It may be that for
some men CAM use is part of an active response to psychological distress. Men are typically
low users of traditional cancer support programs and researchers have suggested that men-
centred support programs that tap into masculine values around self-reliance may be more
acceptable and effective [35,36]. A high use of CAM in this population may reflect the ability
of these products to tap into this dynamic more effectively than traditional services. Similar
results have been reported in a study examining CAM use amongst early-stage breast cancer
patients [37] where it was suggested that women may start using CAMs as a response to psy-
chological symptoms or distress. Although our results suggest that this may also be true for
long-term prostate cancer patients, it should be noted that this finding appears somewhat
inconsistent with that of Steginga et al [33]. In that study, men using CAMs for prostate cancer
were found to be less psychologically distressed than non-users at 12 months after their first
treatment, although the number of users was small (n = 14).
In the present study, perceived control of the course of cancer was found to be associated
with CAM use. This finding has been observed for people with other types of cancer [38] and
is consistent with the view that CAM use might provide men with a sense of being active con-
tributors to their own health and well-being. However, whether such beliefs are good for can-
cer patients is unclear. While optimism can have a positive impact on psychological health,
optimism predicated on fallacy might ultimately lead to greater disappointment and psycho-
logical suffering.
The use of CAMs for prostate cancer was not found to be associated with HRQOL scores
for any of the HRQOL domains examined in the current study. These findings are similar to
those of three previous studies [9–10,32] which found no associations between CAM use and
HRQOL for each of the UCLA-PCI bowel, sexual and urinary domains other than a weak asso-
ciation between CAM use and greater bowel bother (p = 0.035) [32]. Hence, the HRQOL of
men with prostate cancer does not seem to be an important motivator of CAM use, nor does
CAM use seem to be an important contributor to better or worse HRQOL.
This study has several limitations. First, the definition of CAMs encompasses a wide
range of therapies and, consequently, the factors associated with individual CAMs may differ
from the factors associated with all CAMs combined. Second, potential interactions between
the factors associated with CAM use were not examined in this study because there was
insufficient statistical power to do so effectively. Third, a potentially important source of bias
is the non-response of men in the PCOS cohort to the 10-year survey. Somewhat reassur-
ingly, however, respondents (representing 61% of living participants) and non-respondents
had similar demographic and clinical characteristics (S2 Table), except for a higher propor-
tion of non-responders in the oldest age group. Fourth, because CAM use was not measured
in the PCOS cohort at the time of diagnosis, the associations reported in this study are cross-
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sectional in nature. Hence, the data do not allow us to ascribe causal links to our estimates of
association or to make direct comparisons between the CAM use of recently diagnosed men
and long-term survivors.
The findings of our study may be useful for doctors who care for long-term prostate cancer
survivors. In particular, given that CAM use is associated with a number of psychological char-
acteristics, the discovery of a patient’s CAM use may prompt discussion of the potential bene-
fits of counselling. Furthermore, given that some men may be seeking to control the course of
their cancer through CAMs, some users may be more amenable to doctors’ recommendations
for therapies that are potentially beneficial, such as healthy lifestyle interventions.
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